Loading clinical trials...

Post-market Evaluation of the Transition From the Baha Connect System to the Osia System in Adult Bone Conduction Implant Recipients | Clinical Trials | Clareo Health

NOT_YET_RECRUITINGNA

Post-market Evaluation of the Transition From the Baha Connect System to the Osia System in Adult Bone Conduction Implant Recipients

Post-Market Clinical Follow-Up of the Osia System and Evaluation of Benefits of Transitioning From the Baha Connect System to the Osia System in Adult Bone Conduction Implant Recipients With Mixed or Conductive Hearing Loss

NCT07130136•Cochlear

View on ClinicalTrials.gov

Summary

The goal of this interventional study is to confirm the safety and performance of the latest generation Osia System and to examine its benefits compared to the Baha Connect System in adults with mixed or conductive hearing loss who have a pre-existing Baha implant and Abutment (BIA300) and are transitioning to the Osia System. The main questions this study aims to answer are: * Is the safety and performance of the Osia System confirmed by study findings? * What are the benefits of the Osia System compared to the Baha Connect System? Participants will: * Undergo speech performance testing in both quiet and noisy environments * Provide ratings for various questionnaires

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•18 years of age or older
•Implanted with a Cochlear Baha BI300 Implant in combination with a Cochlear Baha BA300 Abutment (Baha Connect)
•Mixed or conductive hearing loss in the ear implanted with the Baha Connect System
•Bone conduction thresholds with pure tone average (PTA4; mean of 0.5, 1, 2, and 4 kHz) of ≤ 55 dB HL in the ear implanted with the Baha Connect System
•Experience of at least 6 months with the Baha Connect System
•Candidate is judged by the investigator to be dissatisfied with their current Baha Connect System due to medical issues, e.g., recurrent adverse skin reactions, and is considered likely to benefit from transitioning to an Osia System
•Candidate is a fluent speaker in the language used to assess speech perception performance
•Candidate is willing and able to provide written informed consent
•Candidate has a retrospective medical record from the time of implantation with the Baha Connect System which the investigational site is authorized to review

Exclusion Criteria

•Candidate with single-sided deafness (air conduction thresholds with pure tone average (PTA4; mean of 0.5, 1, 2 and 3 kHz) of ≤ 20 dB HL in the good ear)
•Candidate with an acute infection (Holgers grade 4) at the implant site at the time of screening
•Unable or unwilling to comply with the requirements of the clinical investigation as determined by the Investigator
•Investigator site personnel directly affiliated with this study and/or their immediate families; immediate family is defined as a spouse, parent, child, or sibling
•Cochlear employees or employees of Contract Research Organizations or contractors engaged by Cochlear for the purposes of this investigation
•Current participation, or participation in another interventional clinical study/trial in the past 30 days, involving an investigational drug or device (unless Cochlear sponsored and determined by the investigator or Sponsor to not impact this investigation)

Locations (3)

Royal National Ear, Nose and Throat and Eastman Dental Hospitals

London, United Kingdom

Nottingham Auditory Implant Programme

Nottingham, United Kingdom

Sheffield Teaching Hospitals

Sheffield, United Kingdom

Key Dates

Start Date

May 1, 2026

Primary Completion Date

November 1, 2028

Completion Date

December 1, 2028

Last Updated

February 11, 2026

Enrollment

ESTIMATED participants

Conditions

Bone ConductionHearing Loss, ConductiveHearing Loss, Mixed

Interventions

Cochlear™ Osia® System

DEVICE

Cochlear™ Baha® System

DEVICE

Contacts

PRS Specialist

CONTACT

+61 2 9428 6555 cltd-prs-admin@cochlear.com

Preschool Hearing Screening

NCT06058767

Hearing LossHearing Disorders in Children+6 more

View study

NOT_YET_RECRUITING

Sentio Systematic Evaluation

NCT07161154

Hearing Loss, Bilateral or UnilateralHearing Loss, Conductive+5 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 11, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Post-market Evaluation of the Transition From the Baha Connect System to the Osia System in Adult Bone Conduction Implant Recipients

Inclusion Criteria

Exclusion Criteria

Preschool Hearing Screening

Sentio Systematic Evaluation

Wide Frequency Band Test of Hearing in Veterans

Audiological Benefit and Improved Quality of Life With Two Bone Conduction Systems: ADHEAR vs. Bonebridge in Experienced Users

Clinical and Health Economic Evaluation With a New Baha® Abutment Combined With a Minimally Invasive Surgical Technique

Comparative Study of Two Surgical Techniques for Soft Tissue Healing and Implant Stability of Cochlear BI300 Implants.